Q1 2022 Results
Company overview
Financial review
2022 priorities
Appendix
References
2022 Novartis full year guidance
Barring unforeseen events; growth vs. PY in cc
Innovative
Medicines
Sales expected to grow mid single digit
Core Oplnc expected to grow mid to high single digit, ahead of sales
Sandoz
Sales expected to be broadly in line with prior year
Core Oplnc expected to decline low to mid single digit
Sales expected to grow mid single digit
Group
Core Oplnc expected to grow mid single digit
Key assumptions
Our guidance assumes that we see a continuing return to normal global healthcare systems, including prescription dynamics,
and that no SandostatinⓇ LAR generics enter in the US
24 Investor Relations | Q1 2022 Results
1 NOVARTIS | Reimagining MedicineView entire presentation